Table 2.
Summary of cost (US dollars) and outcome results in the base-case analysis
| Items | GPP | GM | Incremental |
|---|---|---|---|
| Mean LYs | |||
| iPFS state | 1.68 | 0.74 | 0.94 |
| PD state | 1.25 | 1.54 | −0.29a |
| Total | 2.93 | 2.28 | 0.65 |
| Mean QALYs | |||
| iPFS state | 1.09 | 0.50 | 0.59 |
| PD state | 0.40 | 0.49 | −0.09a |
| Total | 1.49 | 0.99 | 0.50 |
| Cost(US$) | |||
| iPFS state | 23,162.53 | 7,092.97 | 16,069.57 |
| PD state | 12,149.00 | 15,863.48 | −4,118.05a |
| Drug administration cost of 1 st line treatment | 10,432.64 | 1,512.57 | 8,920.07 |
| Drug administration cost of 2nd line treatment | 2,742.94 | 4,344.47 | −1,901.53a |
| AEs management | 307.25 | 100.89 | 206.36 |
| Follow-up visit | 8,609.38 | 6,685.91 | 1,923.47 |
| BSC | 13,235.93 | 10,317.16 | 2,918.77 |
| End-of-life care | 2,470.29 | 2,526.87 | −56.58a |
| Total | 37,781.82 | 25,483.32 | 12,298.51 |
| ICER((US$) | |||
| Per LY | 18,920.78 | ||
| Per QALY | 24,887.67 | ||
GPP Gefitinib + pemetrexed-platinum, GM Gefitinib monotherapy, QALY Quality-adjusted life-year, LY Life-year, ICER Incremental cost-effectiveness ratio, PFS Progression-free survival, PD Progressive disease, OS Overall survival, BSC Best support care, AEs Adverse events
aindicate that the values of the GPP group are lower than those of the GM group